Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.

Author: DingemanseJasper, KankamMartin K, MelchiorMeggane, SidhartaPatricia N

Paper Details 
Original Abstract of the Article :
BACKGROUND: Aprocitentan is an orally active, dual endothelin (ET) receptor antagonist developed for the treatment of hypertension in which, despite available treatments, a medical need exists for drugs with a new mechanism of action. SUBJECTS AND METHODS: In this study, the single- and multiple-do...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435120/

データ提供:米国国立医学図書館(NLM)

Aprocitentan: A Novel Approach to Hypertension

Hypertension, a widespread health concern, necessitates effective and safe treatment options. This study investigates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of aprocitentan, a novel dual endothelin receptor antagonist, in healthy adult and elderly subjects. The researchers conducted a comprehensive evaluation of aprocitentan, administering single and multiple doses to assess its safety, efficacy, and impact on blood pressure. The results demonstrate that aprocitentan was well tolerated across all doses, with a favorable PK profile suitable for once-daily dosing. The study also reveals minimal differences in exposure between different age groups and genders, suggesting its potential for broad applicability.

Aprocitentan: A Promising New Treatment Option

The study's findings suggest that aprocitentan holds significant promise as a new treatment option for hypertension. Its favorable safety profile, effective blood pressure control, and convenient once-daily dosing regimen make it an attractive candidate for patients seeking a well-tolerated and effective treatment. Further research is needed to confirm its long-term efficacy and safety in a broader population.

Navigating the Path to Healthy Blood Pressure

This research highlights the ongoing search for innovative and effective treatments for hypertension. The study's results offer a glimpse into the potential of aprocitentan, a novel dual endothelin receptor antagonist, as a promising new treatment option. It encourages continued research to refine our understanding of this medication and its potential benefits for patients with hypertension.

Dr.Camel's Conclusion

Think of hypertension as a relentless desert wind, my friend, constantly pushing against our health. Aprocitentan, like a sturdy sand dune, could provide a barrier against this relentless force, potentially bringing stability and relief to our cardiovascular system.

Date :
  1. Date Completed 2019-09-16
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

30962677

DOI: Digital Object Identifier

PMC6435120

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.